摘要
肾脏是产生促红细胞生成素(EPO)的主要器官,严重的肾病会造成肾脏功能受损,腹膜透析(PD)虽然能部分替代肾脏功能,但不能完全恢复EPO的正常分泌,可导致骨髓造血功能受到抑制、红细胞生成减少,进而引起贫血。缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)作为新型肾性贫血治疗药物,已被证明可能影响骨代谢。本文通过分析HIF-PHI在调节软骨细胞、成骨细胞、破骨细胞功能以及调控骨代谢相关信号通路等方面的作用机制,旨在为PD患者慢性肾脏病矿物质及骨代谢异常(CKD-MBD)的临床治疗和研究提供理论依据。
The kidney is the main organ that produces erythropoietin(EPO).Severe kidney disease can cause impaired kidney function.Although peritoneal dialysis(PD)can partially replace kidney function,it cannot fully restore the normal secretion of EPO,which can lead to inhibition of bone marrow hematopoietic function and the decrease of erythropoiesis,thus causing anemia.Hypoxia inducible factor prolyl hydroxylase inhibitors(HIF-PHI),as a new therapeutic drug for renal anemia,has been shown to affect bone metabolism.This article aims to provide theoretical basis for the clinical treatment and research of chronic kidney disease-mineral and bone disorder(CKD-MBD)in PD patients by analyzing the mechanism of HIF-PHI in regulating the functions of chondrocytes,osteoblasts,osteoclasts,and regulating bone metabolism related signaling pathways.
作者
胡婷
杨慧
杨梦欣
宁芳
刘丽茹
HU Ting;YANG Hui;YANG Mengxin;NING Fang;LIU Liru(Nephrology Department,the First Affiliated Hospital of Dali University,Dali 671000,China)
出处
《临床医学研究与实践》
2025年第16期181-185,共5页
Clinical Research and Practice
基金
云南省教育厅科学研究基金项目(No.2024Y912)。
关键词
腹膜透析
缺氧诱导因子脯氨酰羟化酶抑制剂
骨代谢
慢性肾脏病矿物质及骨代谢异常
peritoneal dialysis
hypoxia inducible factor prolyl hydroxylase inhibitors
bone metabolism
chronic kidney disease-mineral and bone disorder
